| Objective: In recent years, morbidity and mortality of cancer are increasing obviously, therefore cancer becomes a serious threat to human health. There are still various kinds of problems in conventional chemotherapy , radiotherapy and operative treatment. Tumor immunotherapy is one of newly developed therapeutic methods. However, it is, important for us to get specific tumor antigen in order to develop tumor specific therapeutic vaccine. Tumor cell is "non- self" of normal cell. We define the component which express only in tumor cell but in normal cell as tumor antigen. Immune system can recognize any "non-self" component and remove them through immunological response. In recent years, significant progression in tumor antigen research is the new perspective that T lymphocyte-mediated response is the major manner by which the body to fight tumor cells, especially CD8+ cytotoxict lymphocytes. Tumor antigen is loaded with MHCI molecules and form the tumor peptide complexes which is recognized by T-cell receptor(TCR), the activated T cells will kill tumor cells expressingtumor peptides. Someone outline the pathway as MHC-antigen peptide-TCR mode, the antigen peptide is 8-10 amino acids recognized by CTL and also called tumor specific antigen. Up to date, a series of tumor antigens have been identified and confirmed, include Cancer Testis Antigen family, which express only in cancer testis tissues and tumor tissues but in normal tissues. There is not HLA in testis tissues, therefore CTA is a kind of specific tumor antigen.The relationship between CD109, RFP, BRDT and human tumor has been less reported, especially CD109. To explore whether CD109, RFP, BRDT may become potential molecular targets for new cancer therapy, in the present study tumor and normal tissue samples were obtained from patients undergoing tumor resection, the expression of CD109, RFP, BRDT in tumor and normal tissue was detected through real-time PCR. The present study tried to offer fundamental experiment base for immunological diagnosis and therapy of tumor and has very important theoretical and practical significance.Method: Tumor and normal tissue samples were obtained from patients undergoing tumor resection at Aichi cancer center hospital, the tissue samples were snap frozen in liquid nitrogen, and stored at -80?C until RNA extraction. All samples were obtained according to current ethics regulations. Informed consent was obtained from all subjects before their participation in the study. The protocol was approved by the Aichi cancer center hospital (Nagoya, Japan).We used real-time PCR to analyze CD109, RFP and BRDT expression in different tumor,Result:1. Investigation of Cloning and Expression of CD109 Gene Using Real-Time Fluorescence Quantitative RT-PCRGermline mutation of the RET proto-oncogene are responsible for the development of multiple endocrine neoplasia(MEN)type 2A and 2B. MEN 2A is characterized by the development of medullary thyroid carcinoma(MTC) and pheochromocytoma whereas MEN 2B shows a more complex phenotype with association of MTC, pheochromocytoma, and developmental abnormalities such as mucosal neuroma, hyperganglionosis of the intestinal tract, and marfanoid skeletal changes. To elucidate the mechanisms of development of MEN 2A and MEN 2B phenotypes, we carried out differential display analysis of gene expression using NIH3T3 cells expressing the RET-MEN 2A and RET-MEN 2B mutant proteins. In this study, we cloned one of previously unidentified genes induced by RET-MEN 2B. It turned out to encode mouse orthologue of the human CD109 gene.Using its cDNA fragment, we screened the cDNA library constructed from RNA of NIH-RET(MEN2B)cells and obtained a cDNA clone of 4717 base pairs in length that contained a 4329 bp open reading frame. It encodes a protein of 1442 amino acids having an amino-terminal signal peptide of 22 amino acids and a carboxyl-terminal hydrophobic glycosyl-phosphatidylinositol (GPI)-anchored cleavage-addition site. In addition, a sequence for the thioester bond (CGEQ) was prese...
|
PDF Full Text Request